Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression. Two ETS transcription factors, ERG and ETV1 , were identified as outliers in prostate cancer. We identified recurrent gene fusions of the 5′ untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression. By using fluorescence in situ hybridization, we demonstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or ETV1 . Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer. These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high expression levels of ERG and PEA3 subfamily members in a subset of prostate tumors led to the discovery of common chromosomal rearrangements associated with this human cancer (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Chromosomal rearrangements that result in the overexpression of members of the PEA3 subfamily (ETV1, ETV4, or ETV5) are found less frequently (36, 170, 171).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Rearrangements of ETS loci are a hallmark of prostate cancer with ~50% of tumors showing alterations at an ETS gene locus (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Self-citationA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Self-citationChromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Research works printed but not linked: 5
- I. S. Jeon et al., Oncogene10, 1229 (1995).
- B. Lin et al., Cancer Res.59, 4180 (1999).
- D. E. Afar et al., Cancer Res.61, 1686 (2001).
- S. M. Dhanasekaran et al., FASEB J.19, 243 (2005).
- J. B. Welsh et al., Cancer Res.61, 5974 (2001).
Cited by
Items 801–900 of 1,014
HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology
Shrestha, R., Hodzic, E., Sauerwald, T., Dao, P., Wang, K., Yeung, J., Anderson, S. A., Vandin, F., Haffari, G., Collins, C. C., et al. (2017) · Genome Research · doi:10.1101/gr.221218.117 · Cited by 89
Nelson, M., Millican-Slater, R. A., Forrest, L. C., & Brackenbury, W. J. (2014) · International Journal of Cancer · doi:10.1002/ijc.28890 · Cited by 84
Koo, K. M., Carrascosa, L. G., Shiddiky, M. J. A., & Trau, M. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b01182 · Cited by 77
Transcriptional Regulation during Aberrant Activation of NF-κB Signalling in Cancer
Deka, K., & Li, Y. (2023) · Cells · doi:10.3390/cells12050788 · Cited by 82
Androgen receptor and prostate cancer
Richter, E., Srivastava, S. K., & Dobi, A. L. (2007) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500936 · Cited by 83
“26 In an effort to explain this overexpression, it was shown that the elevated expression of the Ets family members (predominantly ERG) in tumor cells is due to genetic rearrangements, resulting in a fusion of the androgen-inducible TMPRSS2 gene promoter to the ERG or ETV1 loci that may result in the activation of pro…”
BackgroundPellecchia, A., Pescucci, C., Lorenzo, E. D., Luceri, C., Passaro, N., Sica, M., Notaro, R., & Angioletti, M. D. (2012) · Oncogenesis · doi:10.1038/oncsis.2012.20 · Cited by 85
Molecular Pathways in Prostate Cancer
Mazaris, E. M., & Tsiotras, A. (2013) · Nephro-Urology Monthly · doi:10.5812/numonthly.9430 · Cited by 91
Molecular predictors of gemcitabine response in pancreatic cancer
Voutsadakis, I. A. (2011) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v3.i11.153 · Cited by 75
Wu, Y., Wang, X., Wu, F., Huang, R., Xue, F., Liang, G., Tao, M., Cai, P., & Huang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041001 · Cited by 81
Translocation-Related Sarcomas
Mertens, F., Antonescu, C. R., Hohenberger, P., Ladanyi, M., Modena, P., D’Incalci, M., Casali, P. G., Aglietta, M., & Alvegård, T. A. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.06.004 · Cited by 77
Leacock, S. W., Basse, A. N., Chandler, G. L., Kirk, A., Rakheja, D., & Amatruda, J. F. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.007401 · Cited by 90
Lotan, T. L., Wei, W., Morais, C. L., Hawley, S. T., Fazli, L., Hurtado‐Coll, A., Troyer, D. A., McKenney, J. K., Simko, J. P., Carroll, P. R., et al. (2015) · European Urology Focus · doi:10.1016/j.euf.2015.07.005 · Cited by 76
SLC45A3-ELK4 functions as a long non-coding chimeric RNA
Qin, F., Zhang, Y., Liu, J., & Li, H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.007 · Cited by 76
Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma
Verma, A., Jiang, Y., Du, W., Fairchild, L., Melnick, A. M., & Elemento, O. (2015) · Genome Medicine · doi:10.1186/s13073-015-0230-7 · Cited by 92
Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer
Queisser, A., Hagedorn, S., Braun, M., Vogel, W., Duensing, S. M., & Perner, S. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.77 · Cited by 78
Self-citationThe dynamics of cancer chromosomes and genomes
Ye, C. J., Liu, G., Bremer, S. W., & Heng, H. H. (2007) · Cytogenetic and Genome Research · doi:10.1159/000108306 · Cited by 86
Testing mutual exclusivity of ETS rearranged prostate cancer
Svensson, M. A., Lafargue, C. J., MacDonald, T. Y., Pflueger, D., Kitabayashi, N., Santa-Cruz, A. M., Garsha, K. E., Sathyanarayana, U. G., Riley, J., Yun, C. S., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.179 · Cited by 81
Self-citationAttard, G., Sarker, D., Reid, A. H. M., Molife, R., Parker, C. C., & Bono, J. S. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603223 · Cited by 82
Bohrer, L. R., Chen, D., Hallstrom, T. C., & Huang, H. (2010) · Endocrinology · doi:10.1210/en.2010-0436 · Cited by 76
Cell‐free tumour DNA testing for early detection of cancer – a potential future tool
Barbany, G., Arthur, C., Liedén, A., Nordenskjöld, M., Rosenquist, R., Tesi, B., Wallander, K., & Tham, E. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12897 · Cited by 87
Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies
Ralla, B., Stephan, C., Meller, S., Dietrich, D., Kristiansen, G., & Jung, K. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.914888 · Cited by 80
The prostate cancer genome: Perspectives and potential
Barbieri, C. E., & Tomlins, S. A. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.08.025 · Cited by 91
“Fusions involving androgen-regulated genes and members of the ETS transcription factor family are the most common known molecular abnormality in prostate cancer, seen in a majority of cases [14–19].”
BackgroundSelf-citationBiomarkers for Prostate Cancer: From Diagnosis to Treatment
Chen, J., Wang, P., Liu, M., Lyu, F., Ma, M., Ren, X., & Gao, X. (2023) · Diagnostics · doi:10.3390/diagnostics13213350 · Cited by 78
“More than 50% of PCa patients exhibit an increase in ERG gene expression, predominantly characterized by the presence of TM-PRSS2:ERG fusion or other TMPRSS2 fusion partners such as ETV1, ETV4, ETV5, and FLI1 [97,98].”
BackgroundElevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression
DeRosa, C., Furusato, B., Shaheduzzaman, S., Srikantan, V., Wang, Z., Chen, Y., Siefert, M., Ravindranath, L., Young, D., Nau, M. M., et al. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.61 · Cited by 82
Structural mutations in cancer: mechanistic and functional insights
Inaki, K., & Liu, E. T. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.07.002 · Cited by 82
Shao, C., Sun, W., Tan, M., Glazer, C. A., Bhan, S., Zhong, X., Fakhry, C., Sharma, R. B., Westra, W. H., Hoque, M. O., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2992 · Cited by 75
Ahsan, A., Hiniker, S. M., Ramanand, S. G., Nyati, S., Hegde, A., Helman, A., Menawat, R., Bhojani, M. S., Lawrence, T. S., & Nyati, M. K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4294 · Cited by 78
Guerrini, A., Tesei, A., Ferroni, C., Paganelli, G., Zamagni, A., Carloni, S., Donato, M. D., Castoria, G., Leonetti, C., Porru, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5005122 · Cited by 75
Prostasomes as a source of diagnostic biomarkers for prostate cancer
Zijlstra, C., & Stoorvogel, W. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81128 · Cited by 81
Mechanisms of Androgen-Independent Prostate Cancer.
Saraon, P., Drabovich, A. P., Jarvi, K. A., & Diamandis, E. P. (2014) · PubMed Central · Cited by 88
Shin, S.-H., Lee, G. Y., Lee, M., Kang, J., Shin, H., Chun, Y., & Park, J. (2018) · Nature Communications · doi:10.1038/s41467-018-06606-2 · Cited by 79
Graham, T. J., Box, G., Tunariu, N., Crespo, M., Spinks, T. J., Miranda, S., Attard, G., Bono, J. S. D., Eccles, S. A., Davies, F. E., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju033 · Cited by 74
Correlation of UrineTMPRSS2:ERGandPCA3to ERG+ and Total Prostate Cancer Burden
Young, A. M., Palanisamy, N., Siddiqui, J., Wood, D. P., Wei, J. T., Chinnaiyan, A. M., Kunju, L. P., & Tomlins, S. A. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpu7ppwupyg8oh · Cited by 74
Self-citationYang, Y., Blee, A. M., Wang, D., An, J., Pan, Y., Yan, Y., Ma, T., He, Y., Dugdale, J. A., Hou, X., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0686 · Cited by 77
Mazrooei, P., Kron, K. J., Zhu, Y., Zhou, S., Grillo, G., Mehdi, T., Ahmed, M., Severson, T., Guilhamon, P., Armstrong, N. S., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.005 · Cited by 76
Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research
Saranyutanon, S., Deshmukh, S. K., Dasgupta, S., Pai, S. G., Singh, S., & Singh, A. P. (2020) · Cancers · doi:10.3390/cancers12092651 · Cited by 85
“ERG belongs to the ETS family of transcription factors (ERG, ETV1, and ETV4), and its activation is associated with PCa progression in both early- and late-stages [82,83,86].”
BackgroundCrystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism
Han, Y., Zhuang, Q., Sun, B., Lv, W., Wang, S., Xiao, Q., Pang, B., Zhou, Y., Wang, F., Chi, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20675-2 · Cited by 63
Experimental in vitro, ex vivo and in vivo models in prostate cancer research
Sailer, V., Amsberg, G. V., Duensing, S. M., Kirfel, J., Lieb, V., Metzger, E., Offermann, A., Pantel, K., Schüle, R., Taubert, H. W., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00677-z · Cited by 82
Self-citationIntegrative Discovery of Epigenetically Derepressed Cancer Testis Antigens in NSCLC
Glazer, C. A., Smith, I. M., Ochs, M. F., Begum, S., Westra, W. H., Chang, S. S., Sun, W., Bhan, S., Khan, Z. H., Ahrendt, S. A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008189 · Cited by 74
Oncogenic gene fusions in epithelial carcinomas
Prensner, J. R., & Chinnaiyan, A. M. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.11.008 · Cited by 82
Self-citationNoncoding RNAs in Prostate Cancer: The Long and the Short of It
Bolton, E. M., Tuzova, A. V., Walsh, A. L., Lynch, T. H., & Perry, A. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1989 · Cited by 79
Nhili, R., Peixoto, P., Depauw, S., Flajollet, S., Dezitter, X., Munde, M. M., Ismail, M. A., Kumar, A., Farahat, A. A., Stephens, C. E., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks971 · Cited by 79
Kawamata, N., Ogawa, S., Zimmermann, M., Niebuhr, B., Stocking, C., Sanada, M., Hemminki, K., Yamatomo, G., Nannya, Y., Koehler, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711039105 · Cited by 80
Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis
Zhang, L., Shao, L., Creighton, C. J., Zhang, Y., Xin, L., Ittmann, M., & Wang, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3366 · Cited by 74
Albino, D., Civenni, G., Dallavalle, C., Roos, M. M., Jahns, H., Curti, L., Rossi, S., Pinton, S., D’Ambrosio, G., Sessa, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2665 · Cited by 74
Commonality but Diversity in Cancer Gene Fusions
Rabbitts, T. H. (2009) · Cell · doi:10.1016/j.cell.2009.04.034 · Cited by 73
“Initially, a gene encoding a transmembrane serine protease TMPRSS2 (an androgen-responsive gene; Tomlins et al., 2005) was found to be fused with ERG (ETS-Related Gene) by either inversion of chromosome 21 or by interstitial deletion of chromosome 21q22; a TMPRSS2-ETV1 gene fusion was found to be…”
BackgroundZhong, Q., Liu, Z., Lin, Z.-R., Hu, Z.-D., Li, Y., Liu, Y.-M., Zhou, A.-J., Xu, L.-H., Hu, L.-J., Wang, Z.-F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0352 · Cited by 79
Dudka, I., Thysell, E., Lundquist, K., Antti, H., Iglesias-Gato, D., Flores-Morales, A., Bergh, A., Wikström, P., & Gröbner, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-06908-z · Cited by 54
“[5], there has been an intense debate about its usefulness as biomarker for the detection and the stratification of PC [6].”
BackgroundModern biomarkers in prostate cancer diagnosis
Porzycki, P., & Ciszkowicz, E. (2020) · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication · doi:10.5173/ceju.2020.0067r · Cited by 87
Jin, C., Yang, L., Xie, M., Lin, C., Merkurjev, D., Yang, J. C., Tanasă, B., Oh, S., Zhang, J., Ohgi, K. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404303111 · Cited by 79
Exosomes in Prostate Cancer: Putting Together the Pieces of a Puzzle
Soekmadji, C., Russell, P., & Nelson, C. (2013) · Cancers · doi:10.3390/cancers5041522 · Cited by 75
Progensa™ PCA3 test for prostate cancer
Durand, X., Moutereau, S., Xylinas, E. N., & TAILLE, A. D. L. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.122 · Cited by 73
Cell types of origin for prostate cancer
Lee, S. H., & Shen, M. M. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.002 · Cited by 73
ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells
Powell, K., Semaan, L., Conley‐LaComb, M. K., Asangani, I. A., Wu, Y.-M., Ginsburg, K., Williams, J. L., Squire, J. A., Maddipati, K. R., Cher, M. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2352 · Cited by 77
Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2–WNT Signaling Axis
Nandana, S., Tripathi, M., Duan, P., Chu, C.-Y., Mishra, R., Liu, C., Jin, R., Yamashita, H., Zayzafoon, M., Bhowmick, N. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0497 · Cited by 73
EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins
Gollavilli, P. N., Pawar, A., Wilder-Romans, K., Natesan, R., Engelke, C. G., Dommeti, V. L., Krishnamurthy, P. M., Nallasivam, A., Apel, I. J., Xu, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0484 · Cited by 80
Mechanisms of Prostate Cancer Initiation and Progression
Knudsen, B. S., & Vasioukhin, V. I. (2010) · Advances in cancer research · doi:10.1016/b978-0-12-380890-5.00001-6 · Cited by 83
“…event in human prostate cancer, recurrent fusions may also involve other ETS-family genes, such as ETV4 and ETV5 which results in a fusion of sequences in the androgen-driven TMPRSS2 promoter with a portion of the coding region of ERG or ETV1 ETS family transcription factors (Tomlins et al., 2005).”
BackgroundGümüşkaya, B., Gürel, B., Fedor, H. L., Tan, H.-L., Weier, C. A., Hicks, J. L., Haffner, M. C., Lotan, T. L., & Marzo, A. M. D. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.8 · Cited by 74
The potential role of the microbiota in prostate cancer pathogenesis and treatment
Pernigoni, N., Guo, C. W., Gallagher, L., Yuan, W., Colucci, M., Troiani, M., Liu, L., Maraccani, L., Guccini, I., Migliorini, D., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00795-2 · Cited by 77
The Present and Future of Prostate Cancer Urine Biomarkers
Rigau, M., Oliván, M., García, M., Sequeiros, T., Montes, M., Colás, E., Llauradó, M., Planas, J., de Torres, I. M., Moróte, J., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140612620 · Cited by 83
Cangemi, R., Mensah, A. A., Albertini, V., Jain, A., Grand, M. M., Chiorino, G., Catapano, C. V., & Carbone, G. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210953 · Cited by 81
Liu, W., Chang, B., Sauvageot, J., Dimitrov, L. M., Gielzak, M., Li, T., Yan, G., Sun, J., Sun, J., Adams, T. S., et al. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20369 · Cited by 77
The role of proteomics in prostate cancer research: Biomarker discovery and validation
Pin, E., Fredolini, C., & Petricoin, E. F. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.12.012 · Cited by 84
From Bytes to Bedside: Data Integration and Computational Biology for Translational Cancer Research
Mathew, J., Taylor, B. S., Bader, G. D., Pyarajan, S., Antoniotti, M., Chinnaiyan, A. M., Sander, C., Burakoff, S. J., & Mishra, B. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030012 · Cited by 81
Self-citationHolcomb, I. N., Young, J. M., Coleman, I. M., Salari, K., Grove, D. I., Hsu, L.-I., True, L. D., Roudier, M. P., Morrissey, C. M., Higano, C. S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3810 · Cited by 72
Ylipää, A., Kivinummi, K. K., Kohvakka, A., Annala, M., Latonen, L., Scaravilli, M., Kartasalo, K., Leppänen, S.-P., Karakurt, S., Seppälä, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0217 · Cited by 78
Damia, G. L. M. (2020) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2020.111692 · Cited by 75
Pimanda, J. E., Chan, W. Y. I., Donaldson, I. J., Bowen, M., Green, A. R., & Göttgens, B. (2006) · Blood · doi:10.1182/blood-2005-12-4929 · Cited by 69
Vainio, P., Mpindi, J.-P., Kohonen, P. J., Fey, V., Mirtti, T. K., Alanen, K. A., Perälä, M., Kallioniemi, O., & Iljin, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039801 · Cited by 76
The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene
Kelleher, F. C., & McDermott, R. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.006 · Cited by 74
Epigenetic regulation of androgen receptor signaling in prostate cancer
Gao, L., & Alumkal, J. J. (2010) · Epigenetics · doi:10.4161/epi.5.2.10778 · Cited by 73
Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review
Sanguedolce, F., Cormio, A., Brunelli, M., D’Amuri, A., Carrieri, G., Bufo, P., & Cormio, L. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.12.001 · Cited by 76
TMPRSS2-ERG fusion promotes prostate cancer metastases in bone
Deplus, R., Delliaux, C., Marchand, N., Flourens, A., Vanpouille, N., Leroy, X., de Launoit, Y., & Duterque‐Coquillaud, M. (2016) · Oncotarget · doi:10.18632/oncotarget.14399 · Cited by 72
Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity
Feng, F. Y.-C., Varambally, S., Tomlins, S. A., Chun, P. Y., Lopez, C. A., Li, X., Davis, M. A., Chinnaiyan, A. M., Lawrence, T. S., & Nyati, M. K. (2006) · Oncogene · doi:10.1038/sj.onc.1210129 · Cited by 72
Self-citationLawson, A. R. J., Hindley, G. F. L., Forshew, T., Tatevossian, R. G., Jamie, G. A., Kelly, G. P., Neale, G. A., Ma, J., Jones, T. A., Ellison, D. W., et al. (2011) · Genome Research · doi:10.1101/gr.115782.110 · Cited by 79
“Gene fusions have also been identified in several adult carcinomas, such as prostate cancer (Tomlins et al. 2005), adenoid cystic carcinomas (Persson et al.”
BackgroundFusionCancer: a database of cancer fusion genes derived from RNA-seq data
Wang, Y., Wu, N., Liu, J., Wu, Z., & Dong, D. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0310-4 · Cited by 94
Fusion in the ETS gene family and prostate cancer
Narod, S. A., Seth, A. K., & Nam, R. K. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604558 · Cited by 76
Exploring genomic profiles of hepatocellular carcinoma
Woo, H. G., Park, E. S., Thorgeirsson, S. S., & Kim, Y. J. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20691 · Cited by 74
Vellaichamy, A., Sreekumar, A., Strahler, J. R., Rajendiran, T., Yu, J., Varambally, S., Li, Y., Omenn, G. S., Chinnaiyan, A. M., & Nesvizhskii, A. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007075 · Cited by 71
Self-citationon behalf of the Trans-Atlantic Prostate Group, Foster, C. S., Dodson, A. R., Ambroisine, L., Fisher, G., Møller, H., Clark, J., Attard, G., Bono, J. S. D., Scardino, P. T., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605227 · Cited by 70
High mitochondria content is associated with prostate cancer disease progression
Grupp, K., Jedrzejewska, K., Tsourlakis, M. C., Koop, C., Wilczak, W., Adam, M., Quaas, A., Sauter, G., Simon, R., Izbicki, J. R., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-145 · Cited by 76
Abate, F., Zairis, S., Ficarra, E., Acquaviva, A., Wiggins, C. H., Frattini, V., Lasorella, A., Iavarone, A., Inghirami, G. G., & Rabadán, R. (2014) · BMC Systems Biology · doi:10.1186/s12918-014-0097-z · Cited by 77
DNA Binding by the ETS Protein TEL (ETV6) Is Regulated by Autoinhibition and Self-association
Green, S. M., Coyne, H. J., McIntosh, L. P., & Graves, B. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.096958 · Cited by 69
Heemers, H. V., Regan, K. M., Dehm, S. M., & Tindall, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1917 · Cited by 68
PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer
Teschendorff, A. E., Naderi, A., Barbosa‐Morais, N. L., & Caldas, C. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl174 · Cited by 69
Ganguly, S. S., Li, X., & Miranti, C. K. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00364 · Cited by 77
A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein
Pop, M. S., Stransky, N., Garvie, C. W., Theurillat, J.-P., Hartman, E. C., Lewis, T. A., Zhong, C., Culyba, E. K., Lin, F., Daniels, D. S., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0689 · Cited by 65
MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer
Chakravarthi, B. V. S. K., Goswami, M. T., Pathi, S. S., Robinson, A. D., Cieslik, M. P., Chandrashekar, D. S., Agarwal, S., Siddiqui, J., Daignault, S. D., Carskadon, S. L., et al. (2016) · Oncogene · doi:10.1038/onc.2016.164 · Cited by 72
Self-citationGupta, S. K., Li, J., Kemeny, G., Bitting, R. L., Beaver, J., Somarelli, J. A., Ware, K. E., Gregory, S. G., & Armstrong, A. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1211 · Cited by 72
Valle, J. A. B.-D., Zheng, Q., Hicks, J. L., Fedor, H. L., Trock, B. J., Morrissey, C. M., Corey, E., Cornish, T. C., Sfanos, K. S., & Marzo, A. M. D. (2017) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqx094 · Cited by 69
Cancer Progress and Priorities: Prostate Cancer
Kensler, K. H., & Rebbeck, T. R. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0412 · Cited by 75
Lotan, T. L., Tomlins, S. A., Bismar, T. A., van der Kwast, T., Grignon, D. J., Egevad, L., Kristiansen, G., Pritchard, C. C., Rubin, M. A., & Bubendorf, L. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001450 · Cited by 79
Self-citationProtein 4.1B suppresses prostate cancer progression and metastasis
Wong, S. Y., Haack, H., Kissil, J. L., Barry, M., Bronson, R. T., Shen, S. S., Whittaker, C. A., Crowley, D. G., & Hynes, R. O. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705499104 · Cited by 69
Barwick, B. G., Abramovitz, M., Kodani, M., Moreno, C. S., Nam, R. K., Tang, W., Bouzyk, M., Seth, A. K., & Leyland-Jones, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605519 · Cited by 68
5-alpha reductase inhibitors use in prostatic disease and beyond
Chislett, B., Chen, D. C., Perera, M., Chung, E., Bolton, D. M., & Qu, L. G. (2023) · Translational Andrology and Urology · doi:10.21037/tau-22-690 · Cited by 73
Jia, L., Shen, H. C., Wantroba, M., Khalid, O., Liang, G., Wang, Q., Gentzschein, E., Pinski, J. K., Stanczyk, F. Z., Jones, P. A., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00581-06 · Cited by 66
Razak, A. R. A., Hotte, S. J., Siu, L. L., Chen, E. X., Hirte, H. W., Powers, J., Walsh, W., Stayner, L.-A., Laughlin, A., Novotny-Diermayr, V, et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.13 · Cited by 66
Björkman, M. L., Iljin, K., Halonen, P., Sara, H., Kaivanto, E., Nees, M., & Kallioniemi, O. (2008) · International Journal of Cancer · doi:10.1002/ijc.23885 · Cited by 73
Deregulation of an imprinted gene network in prostate cancer
Ribarska, T., Goering, W., Droop, J., Bastian, K.-M., Ingenwerth, M., & Schulz, W. A. (2014) · Epigenetics · doi:10.4161/epi.28006 · Cited by 73
Bismar, T. A., Dolph, M., Teng, L., Liu, S., & Donnelly, B. J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.001 · Cited by 71
Metadata
- Authors
- Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109–0602, USA.
- Corresponding author
- Chinnaiyan, Arul M.
- ORCID
- Venue
- Science
- Published
- 2005-10-28
- Volume
- 310
- Issue
- 5748
- Pages
- 644-648
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2121158863
- Cited by
- 3,846
- References
- 32
- Citations by year
- 2026: 77 · 2025: 99 · 2024: 82 · 2023: 108 · 2022: 137 · 2021: 163 · 2020: 187 · 2019: 172 · 2018: 178 · 2017: 218 · 2016: 209 · 2015: 244 · 2014: 271 · 2013: 309 · 2012: 279
- FWCI
- 114.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG021404, R01 AG 21404)
- National Cancer Institute (UO1 CA111275-01, P50-CA-69568, U01CA111275, R01CA097063, R01 CA97063, 5P30 CA 46592, P50CA069568, P30CA046592)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- TMPRSS2-ERG fusion, prostate cancer, ETS transcription factors, chromosomal rearrangements, gene fusion, molecular diagnosis
- MeSH terms
- Transcriptional Regulator ERG, Androgens, DNA-Binding Proteins, Humans, Male, Membrane Proteins, Molecular Sequence Data, Neoplasm Proteins, Prostatic Neoplasms, Serine Endopeptidases, Transcription Factors, Translocation, Genetic, Gene Rearrangement, Oncogene Proteins, Fusion, Trans-Activators, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, In Situ Hybridization, Fluorescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.